Results 61 to 70 of about 218,733 (151)
Atypical giant prolactinoma with frontal lobe manifestations [PDF]
BMJ Case Reports, 2018 Prolactinomas having the diameter above 4 cm are termed ‘giant prolactinomas’.1 2 Their incidence is approximately 2%–3% of all prolactinomas1. These are associated with very high prolactin concentration and numerous neurological sequelae, arising from their extension into surrounding structures.
Muhammad Fahad Arshad +2 more
openaire +2 more sources
, 2022 Additional file 5: Figure S4. AS events in SF3B1 mutant human prolactinoma and MRI scans of the estradiol-induced prolactinoma model. (A) Volcano plot showing the differential alternative splicing events in SF3B1 mutant vs.
Jing Guo (102972) +7 more
core +1 more source
Giant prolactinoma: the sound of silence
Endocrinology Studies, 2014 Prolactinomas typically present with oligoamenorrhea or galactorrhea in woman and headaches, visual changes or impotence in men with auditory symptoms being a rare presentation. We describe a case of a man who presented with bilateral hearing loss and was found to have a giant prolactinoma.
Shira R. Saul, Maya P. Raghuwanshi
openaire +1 more source
Giant prolactinoma case with side effects due to cabergoline
, 2020 Dopamine agonists should usually be the first treatment for patients with prolactinomas of all sizes, because these drugs decrease serum prolactin concentrations and decrease the size of most lactotroph adenomas. Cabergoline is preferred first.
Hüseyin Dursun +3 more
core +1 more source
, 2022 Additional file 3: Figure S2.SF3B1-R625H alters the transcriptome in GH3 cells and human prolactinoma. (A) Volcano plot comparing mRNA expression between Sf3b1 mutant vs. wild-type GH3 cells.
Jing Guo (102972) +7 more
core +1 more source
Somatostatin Receptor Scintigraphy of a Patient with a Giant Invasive Prolactinoma
, 1999 SummaryA 41-year-old with a giant prolactinoma underwent ln-111 pentetreotide (Octreotide) imaging showing very intense tracer uptake in the region of the anterior skull base.
N. I. Bohnen +3 more
core +1 more source
Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
Endocrine OncologyProlactinomas are the most common hypersecretory pituitary adenoma. The traditional first-line therapy is dopamine agonists (DAs), which are highly effective and tolerated in the majority of cases.
Edward Mignone +4 more
doaj +1 more source
Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment
Endocrinology, Diabetes & Metabolism Case Reports, 2019 A 32-year-old woman presented with primary amenorrhoea, prolactin (PRL) level of 154 150 mIU/L and was diagnosed with a giant pituitary adenoma measuring maximum 6.2 cm.
L I Astaf’eva +5 more
doaj +1 more source
Journal of Clinical & Translational EndocrinologyObjectives: Dopamine agonists serve as first-line therapies for most giant prolactinomas. The objective of this study was to assess the differential impact of dopamine agonist dosing strategies on biochemical (prolactin normalisation) and radiological ...
Hána Václav Jr. +11 more
doaj +1 more source
The efficacy of dopamine agonist therapy in a young man with a giant prolactinoma: case report
, 2017 Prolactinomas are the most common of hormone secreting pituitary adenomas. Patients with prolactinomas generally have a benign prognosis. An algorithm is currently available for managing of this disease.
Alexandr I. Tsiberkin +3 more
core +1 more source